Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574132 · ClinicalTrials.gov registry record · Phase 3
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
A Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,331
- Enrollment target
NCT00574132: Completed Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00574132 is a Phase 3 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 1,331 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574132, a Phase 3 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,331 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Interventions
- DRUG Placebo Control
- DRUG Bapineuzumab 0.5 mg/kg
- DRUG Bapineuzumab 1.0 m/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
What the finished NCT00574132 record still lists
NCT00574132 is an interventional study that assigns participants to a tested intervention. Its 1,331 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT00574132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00574132 about?
NCT00574132 is a clinical study titled "Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)". This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Pat...
What is the current status of trial NCT00574132?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,331 participants. The study started on 2007-12. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00574132?
The interventions under investigation include: Placebo Control (DRUG), Bapineuzumab 0.5 mg/kg (DRUG), Bapineuzumab 1.0 m/kg (DRUG).
Who is sponsoring clinical trial NCT00574132?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00574132's enrollment target sits among peer trials
1,331 183rd of 2000 higher than 1,818 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia